메뉴 건너뛰기
Evidence-Based Practice
Volumn 12, Issue 9, 2009, Pages 14-15
Extended interval bisphosphonate dosing: A focus on zoledronic acid (Reclast®)
Author keywords

[No Author keywords available]
Indexed keywords

EID: 77956021575     PISSN: 10954120     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (1)
References (7)
  • 1
    • 77956052494 scopus 로고    scopus 로고
    • East Hanover, NJ: Novartis Pharmaceuticals Corporation; revised, March, Accessed August 3, 2009
    • Reclast (zoledronic acid) injection [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; revised March 2009. www.reclast.com. Accessed August 3, 2009.
    • (2009) Reclast (Zoledronic Acid) Injection [Prescribing Information]
  • 2
    • 6844257412 scopus 로고    scopus 로고
    • National Osteoporosis Foundation, Accessed August 3, [LOE 5]
    • National Osteoporosis Foundation. Fast facts on osteoporosis. http://www.nof.org/osteoporosis/diseasetacts.htm. Accessed August 3. 2009. [LOE 5]
    • (2009) Fast Facts on Osteoporosis
  • 3
    • 43449107330 scopus 로고    scopus 로고
    • National Osteoporosis Foundation, Accessed August 3, [LOE 5]
    • National Osteoporosis Foundation. Clinician's guide to prevention and treatment of Osteoporosis. http://www.nof.org/professionais/clinicians-guide- landing-pg.htm. Accessed August 3, 2009. [LOE 5]
    • (2009) Clinician's Guide to Prevention and Treatment of Osteoporosis
  • 4
    • 27844518271 scopus 로고    scopus 로고
    • Compliance with osteoporosis medications
    • [LOE 2b]
    • Solomon DH. Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005; 165(20):2414-2419. [LOE 2b]
    • (2005) Arch Intern Med. , vol.165 , Issue.20 , pp. 2414-2419
    • Solomon, D.H.1    Avorn, J.2    Katz, J.N.3
  • 5
    • 34247866550 scopus 로고    scopus 로고
    • Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    • for the HORIZON Pivotal Fracture Trial, [LOE 1b]
    • Black DM, Delmas PD, Eastell R, et al; for the HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-1822. [LOE 1b]
    • (2007) N Engl J Med. , vol.356 , Issue.18 , pp. 1809-1822
    • Black, D.M.1    Delmas, P.D.2    Eastell, R.3
  • 6
    • 35748967004 scopus 로고    scopus 로고
    • Zoledronic acid and clinical fractures and mortality after hip fracture
    • for the HORIZON Recurrent Fracture Trial, [LOE 1b]
    • Lyles KW, Colon-Emeric CS. Magaziner JS, et al; for the HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357(18):1799-1809. [LOE 1b]
    • (2007) N Engl J Med. , vol.357 , Issue.18 , pp. 1799-1809
    • Lyles, K.W.1    Colon-Emeric, C.S.2    Magaziner, J.S.3
  • 7
    • 51749102927 scopus 로고    scopus 로고
    • Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: Enhanced efficacy by enhanced compliance
    • [LOE 3a]
    • Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med. 2008; 264(4):315-332. [LOE 3a]
    • (2008) J Intern Med. , vol.264 , Issue.4 , pp. 315-332
    • Boonen, S.1    Vanderschueren, D.2    Venken, K.3    Milisen, K.4    Delforge, M.5    Haentjens, P.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.